AML-335: Treating Hematologic Oncology Patients in the Developing World During the COVID-19 Pandemic

MLA

Artashes Tadevosyan, et al. “AML-335: Treating Hematologic Oncology Patients in the Developing World During the COVID-19 Pandemic.” Clinical Lymphoma Myeloma and Leukemia, Sept. 2020. EBSCOhost, https://doi.org/10.1016/s2152-2650(20)30759-x.

APA

Artashes Tadevosyan, Armine Farmazyan, Maria Badikyan, Nare Martirosyan, Karen Meliksetyan, Liana Hambardzumyan, Tatevik Grigoryan, Miranush Saaryan, Yervand Hakobyan, Gevorg Tamamyan, Hayk Grigoryan, & Samvel Danielyan. (2020). AML-335: Treating Hematologic Oncology Patients in the Developing World During the COVID-19 Pandemic. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/s2152-2650(20)30759-x

Chicago

Artashes Tadevosyan, Armine Farmazyan, Maria Badikyan, Nare Martirosyan, Karen Meliksetyan, Liana Hambardzumyan, Tatevik Grigoryan, et al. 2020. “AML-335: Treating Hematologic Oncology Patients in the Developing World During the COVID-19 Pandemic.” Clinical Lymphoma Myeloma and Leukemia, September. doi:10.1016/s2152-2650(20)30759-x.